Fig 3. High salt treatment induced higher plasma TXA₂ level and blood pressure, and affected fetal growth in pregnant WT mice.

Plasma TXB₂, a TXA₂ metabolite (A), and 6-keto-PGF1α (E) levels were detected by EIA (n = 10/group). (B) MAP was measured from gestational days 11–18 and normalized to corresponding baseline pressure (n = 10/group). Arrow marks the beginning of high salt treatment. Pup weight (C) and size (D) were measured immediately after delivery. Data are presented as mean±SEM. *P<0.05, **P<0.01, ***P<0.001.